Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

HBM Healthcare Investments

SWX:HBMN
Snowflake Description

Outstanding track record and undervalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HBMN
SWX
CHF1B
Market Cap
  1. Home
  2. CH
  3. Diversified Financials
Company description

HBM Healthcare Investments AG specializes in fund of funds and direct investments in middle market and mature companies. The last earnings update was 69 days ago. More info.


Add to Portfolio Compare Print
  • HBM Healthcare Investments is a fund or ETF! Currently our data availability for these is poor, we only recommend using them as part of a portfolio.
  • HBM Healthcare Investments has significant price volatility in the past 3 months.
HBMN Share Price and Events
7 Day Returns
4.9%
SWX:HBMN
-4.9%
CH Capital Markets
2.7%
CH Market
1 Year Returns
14.3%
SWX:HBMN
-30.5%
CH Capital Markets
-5.4%
CH Market
HBMN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
HBM Healthcare Investments (HBMN) 4.9% -9% -12.9% 14.3% 71.7% 77.8%
CH Capital Markets -4.9% -19.4% -33.2% -30.5% -41.4% -57.7%
CH Market 2.7% -9.4% -13.8% -5.4% 3.6% -3.4%
1 Year Return vs Industry and Market
  • HBMN outperformed the Capital Markets industry which returned -30.5% over the past year.
  • HBMN outperformed the Market in Switzerland which returned -5.4% over the past year.
Price Volatility
HBMN
Industry
5yr Volatility vs Market

Value

 Is HBM Healthcare Investments undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of HBM Healthcare Investments to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for HBM Healthcare Investments.

SWX:HBMN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Excess Returns Model
Stable EPS Median Return on Equity from the past 5 years.
= Stable Book Value * Return on Equity
= CHF171.48 * 11.5%
CHF19.77
Book Value of Equity per Share Median Book Value from the past 5 years. CHF171.48
Discount Rate (Cost of Equity) See below 4.2%
Perpetual Growth Rate 10-Year CH Government Bond Rate -0.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SWX:HBMN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CH Govt Bond Rate -0.6%
Equity Risk Premium S&P Global 5.4%
Capital Markets Unlevered Beta Simply Wall St/ S&P Global 0.74
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.743 (1 + (1- 18%) (11.96%))
0.877
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.88
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.55% + (0.877 * 5.44%)
4.22%

Discounted Cash Flow Calculation for SWX:HBMN using Excess Returns Model Model

The calculations below outline how an intrinsic value for HBM Healthcare Investments is arrived at using the Excess Return Model. This approach is used for finance firms where free cash flow is difficult to estimate.

In the Excess Return Model the value of a firm can be written as the sum of capital invested currently in the firm and the present value of excess returns that the firm expects to make in the future.

The model is sensitive to the Return on Equity of the company versus the Cost of Equity, how these are calculated is detailed below the main calculation.

Note the calculations below are per share.

See our documentation to learn about this calculation.

SWX:HBMN Value of Excess Returns
Calculation Result
Excess Returns = (Stable Return on equity – Cost of equity) (Book Value of Equity per share)
= (11.5% – 4.22%) * CHF171.48)
CHF12.54
Terminal Value of Excess Returns = Excess Returns / (Cost of Equity - Expected Growth Rate)
= CHF12.54 / (4.22% - -0.55%)
CHF262.87
Value of Equity = Book Value per share + Terminal Value of Excess Returns
= CHF171.48 + CHF262.87
CHF434.35
SWX:HBMN Discount to Share Price
Calculation Result
Value per share (CHF) From above. CHF434.35
Current discount Discount to share price of CHF192.00
= -1 x (CHF192.00 - CHF434.35) / CHF434.35
55.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price HBM Healthcare Investments is available for.
Intrinsic value
>50%
Share price is CHF192 vs Future cash flow value of CHF434.35
Current Discount Checks
For HBM Healthcare Investments to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • HBM Healthcare Investments's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • HBM Healthcare Investments's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for HBM Healthcare Investments's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are HBM Healthcare Investments's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SWX:HBMN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in CHF CHF56.55
SWX:HBMN Share Price ** SWX (2020-04-03) in CHF CHF192
Switzerland Capital Markets Industry PE Ratio Median Figure of 13 Publicly-Listed Capital Markets Companies 16.53x
Switzerland Market PE Ratio Median Figure of 175 Publicly-Listed Companies 16.23x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of HBM Healthcare Investments.

SWX:HBMN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SWX:HBMN Share Price ÷ EPS (both in CHF)

= 192 ÷ 56.55

3.4x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • HBM Healthcare Investments is good value based on earnings compared to the CH Capital Markets industry average.
  • HBM Healthcare Investments is good value based on earnings compared to the Switzerland market.
Price based on expected Growth
Does HBM Healthcare Investments's expected growth come at a high price?
Raw Data
SWX:HBMN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 3.4x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-23.6%per year
Switzerland Capital Markets Industry PEG Ratio Median Figure of 9 Publicly-Listed Capital Markets Companies 1.11x
Switzerland Market PEG Ratio Median Figure of 120 Publicly-Listed Companies 1.81x

*Line of best fit is calculated by linear regression .

SWX:HBMN PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 3.4x ÷ -23.6%

-0.14x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • HBM Healthcare Investments earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on HBM Healthcare Investments's assets?
Raw Data
SWX:HBMN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in CHF CHF220.48
SWX:HBMN Share Price * SWX (2020-04-03) in CHF CHF192
Switzerland Capital Markets Industry PB Ratio Median Figure of 16 Publicly-Listed Capital Markets Companies 0.92x
Switzerland Market PB Ratio Median Figure of 216 Publicly-Listed Companies 1.33x
SWX:HBMN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SWX:HBMN Share Price ÷ Book Value per Share (both in CHF)

= 192 ÷ 220.48

0.87x

* Primary Listing of HBM Healthcare Investments.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • HBM Healthcare Investments is good value based on assets compared to the CH Capital Markets industry average.
X
Value checks
We assess HBM Healthcare Investments's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Capital Markets industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Capital Markets industry average (and greater than 0)? (1 check)
  5. HBM Healthcare Investments has a total score of 5/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is HBM Healthcare Investments expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-23.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is HBM Healthcare Investments expected to grow at an attractive rate?
  • HBM Healthcare Investments's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of -0.6%.
Growth vs Market Checks
  • HBM Healthcare Investments's earnings are expected to decrease over the next 1-3 years, this is below the Switzerland market average.
  • Unable to compare HBM Healthcare Investments's revenue growth to the Switzerland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
SWX:HBMN Future Growth Rates Data Sources
Data Point Source Value (per year)
SWX:HBMN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -23.6%
Switzerland Capital Markets Industry Earnings Growth Rate Market Cap Weighted Average 4.7%
Switzerland Capital Markets Industry Revenue Growth Rate Market Cap Weighted Average 1.2%
Switzerland Market Earnings Growth Rate Market Cap Weighted Average 8.4%
Switzerland Market Revenue Growth Rate Market Cap Weighted Average 2.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SWX:HBMN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in CHF Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SWX:HBMN Future Estimates Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-03-31 -4 136
2021-03-31 -4 227
2020-04-05
2020-03-31 -4 42
SWX:HBMN Past Financials Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income *
2019-12-31 400 -4 393
2019-09-30 141 -4 135
2019-06-30 224 -4 218
2019-03-31 216 -3 209
2018-12-31 117 -3 112
2018-09-30 285 -3 279
2018-06-30 260 -3 254
2018-03-31 121 -3 116
2017-12-31 248 -3 242
2017-09-30 131 -3 126
2017-06-30 93 -3 88
2017-03-31 142 -2 137

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • HBM Healthcare Investments's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Unable to determine if HBM Healthcare Investments is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SWX:HBMN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from HBM Healthcare Investments Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:HBMN Future Estimates Data
Date (Data in CHF Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-03-31 19.47 19.47 19.47 1.00
2021-03-31 32.58 32.58 32.58 1.00
2020-04-05
2020-03-31 6.07 6.07 6.07 1.00
SWX:HBMN Past Financials Data
Date (Data in CHF Millions) EPS *
2019-12-31 56.55
2019-09-30 19.35
2019-06-30 31.29
2019-03-31 30.05
2018-12-31 16.03
2018-09-30 40.09
2018-06-30 36.45
2018-03-31 16.55
2017-12-31 35.30
2017-09-30 17.73
2017-06-30 12.29
2017-03-31 18.96

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if HBM Healthcare Investments will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess HBM Healthcare Investments's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
HBM Healthcare Investments has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has HBM Healthcare Investments performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare HBM Healthcare Investments's growth in the last year to its industry (Capital Markets).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • HBM Healthcare Investments's year on year earnings growth rate has been positive over the past 5 years.
  • HBM Healthcare Investments's 1-year earnings growth exceeds its 5-year average (252.7% vs 11.1%)
  • HBM Healthcare Investments's earnings growth has exceeded the CH Capital Markets industry average in the past year (252.7% vs 4.1%).
Earnings and Revenue History
HBM Healthcare Investments's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from HBM Healthcare Investments Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:HBMN Past Revenue, Cash Flow and Net Income Data
Date (Data in CHF Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 399.82 393.40 2.98
2019-09-30 141.08 134.60 2.94
2019-06-30 224.26 217.71 2.95
2019-03-31 215.50 209.07 2.92
2018-12-31 116.89 111.55 1.88
2018-09-30 284.51 279.19 1.92
2018-06-30 259.62 254.42 1.95
2018-03-31 121.09 115.87 1.91
2017-12-31 248.04 242.25 2.32
2017-09-30 131.18 125.54 2.29
2017-06-30 93.45 87.77 2.28
2017-03-31 142.41 136.77 2.30
2016-12-31 -129.30 -97.05 -20.36
2016-09-30 139.37 155.80 -6.54
2016-06-30 40.36 46.37 -2.97
2016-03-31 27.22 23.81 0.84
2015-12-31 152.29 121.50 29.48
2015-09-30 73.72 34.17 40.58
2015-06-30 207.68 163.73 52.17
2015-03-31 304.40 257.51 60.88
2014-12-31 409.80 347.61 60.36
2014-09-30 337.05 296.82 38.50
2014-06-30 365.71 338.20 26.00
2014-03-31 370.54 353.52 15.90
2013-12-31 338.15 326.00 11.10
2013-09-30 232.78 221.27 10.27
2013-06-30 116.74 105.50 9.92

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • HBM Healthcare Investments has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • HBM Healthcare Investments used its assets more efficiently than the CH Capital Markets industry average last year based on Return on Assets.
  • HBM Healthcare Investments has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess HBM Healthcare Investments's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Capital Markets industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
HBM Healthcare Investments has a total score of 6/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is HBM Healthcare Investments's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up HBM Healthcare Investments's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • HBM Healthcare Investments's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • HBM Healthcare Investments's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of HBM Healthcare Investments's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from HBM Healthcare Investments Company Filings, last reported 3 months ago.

SWX:HBMN Past Debt and Equity Data
Date (Data in CHF Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 1,531.75 159.52 6.47
2019-09-30 1,368.54 155.48 2.77
2019-06-30 1,393.47 109.44 11.96
2019-03-31 1,318.26 99.40 4.70
2018-12-31 1,190.52 151.36 4.98
2018-09-30 1,286.11 151.32 5.21
2018-06-30 1,186.20 139.28 6.67
2018-03-31 1,157.90 99.24 6.52
2017-12-31 1,128.25 159.20 7.70
2017-09-30 1,060.86 152.15 5.56
2017-06-30 979.11 152.11 11.98
2017-03-31 1,095.76 99.07 6.12
2016-12-31 930.64 99.03 80.46
2016-09-30 983.27 98.99 114.39
2016-06-30 942.70 98.95 101.02
2016-03-31 1,034.83 98.91 6.61
2015-12-31 1,114.85 98.87 58.75
2015-09-30 925.49 98.83 108.03
2015-06-30 991.49 0.00 130.69
2015-03-31 1,074.19 0.00 140.38
2014-12-31 1,062.63 0.00 102.74
2014-09-30 954.28 0.00 101.56
2014-06-30 885.57 0.00 21.44
2014-03-31 920.34 0.00 46.92
2013-12-31 816.27 0.00 67.62
2013-09-30 750.02 0.00 50.99
2013-06-30 659.49 0.00 68.10
  • HBM Healthcare Investments's level of debt (10.4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if HBM Healthcare Investments's debt level has increased without past 5-year debt data.
  • Operating cash flow is negative therefore debt is not well covered.
  • Interest payments on debt are well covered by earnings (EBIT is 162.5x coverage).
X
Financial health checks
We assess HBM Healthcare Investments's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. HBM Healthcare Investments has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is HBM Healthcare Investments's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
3.91%
Current annual income from HBM Healthcare Investments dividends. Estimated to be 5.09% next year.
If you bought CHF2,000 of HBM Healthcare Investments shares you are expected to receive CHF78 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • HBM Healthcare Investments's pays a higher dividend yield than the bottom 25% of dividend payers in Switzerland (2.05%).
  • HBM Healthcare Investments's dividend is below the markets top 25% of dividend payers in Switzerland (4.46%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SWX:HBMN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Switzerland Capital Markets Industry Average Dividend Yield Market Cap Weighted Average of 13 Stocks 6%
Switzerland Market Average Dividend Yield Market Cap Weighted Average of 159 Stocks 3.3%
Switzerland Minimum Threshold Dividend Yield 10th Percentile 1.3%
Switzerland Bottom 25% Dividend Yield 25th Percentile 2%
Switzerland Top 25% Dividend Yield 75th Percentile 4.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SWX:HBMN Future Dividends Estimate Data
Date (Data in CHF) Dividend per Share (annual) Avg. No. Analysts
2022-03-31 9.99 1.00
2021-03-31 9.55 1.00
2020-04-05
2020-03-31 8.46 1.00
SWX:HBMN Past Annualized Dividends Data
Date (Data in CHF) Dividend per share (annual) Avg. Yield (%)
2019-05-16 7.500 3.765
2018-06-06 7.000 4.236
2018-05-18 7.000 4.192
2017-05-15 5.800 4.568
2016-05-30 5.500 5.411
2016-05-18 5.500 5.655
2015-06-03 5.500 5.585
2015-05-13 5.500 5.086
2014-05-12 3.000 3.277
2013-05-30 1.500 2.251

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, HBM Healthcare Investments has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but HBM Healthcare Investments only paid a dividend in the past 7 years.
Current Payout to shareholders
What portion of HBM Healthcare Investments's earnings are paid to the shareholders as a dividend.
  • Dividends paid are thoroughly covered by earnings (7.5x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (2.3x coverage).
X
Income/ dividend checks
We assess HBM Healthcare Investments's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can HBM Healthcare Investments afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. HBM Healthcare Investments has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of HBM Healthcare Investments's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Andreas Wicki
COMPENSATION CHF172,461
AGE 61
TENURE AS CEO 19.3 years
CEO Bio

Dr. Andreas Wicki, Ph.D. serves as the Chief Executive Officer of HBM Healthcare Investments (Cayman) Ltd. Dr. Wicki is a successful healthcare entrepreneur and investor with over 25 years of experience in the pharmaceutical and biotechnology industries. Dr. Wicki has been the Chief Executive Officer of HBM Partners Ltd. since 2001. Previously, he had been a Director at the firm. Dr. Wicki serves as Chief Executive Officer of HBM Bioventures AG. He serves as Chief Executive Officer and Director of HBM BioCapital I LP and HBM BioCapital II LP. He served as the President of Anawa Holding Ag. He has been the Chief Executive Officer of HBM Healthcare Investments AG since 2001. He was a Co-owner and Chief Executive Officer at ANAWA Laboratorien AG. He was Co-Owner and Chief Executive Officer of ANAWA Holding AG and Clinserve AG, two contract research organizations specializing in analytical services. Dr. Wicki served as Vice Chairman at Basilea Pharmaceutica AG until April 29, 2009. Dr. Wicki has been a Director of Pacira Pharmaceuticals, Inc since December 2006. He serves as a Board member of HBM Bioventures (Cayman) Ltd. Dr. Wicki serves as a Director of Harmony Biosciences, LLC. Dr. Wicki serves as a Director of MDS Pharma Services Switzerland AG, Celerion Switzerland AG, Buchler GmbH and COSMIX molecular biologicals GmbH. He serves as a Director of Vitaeris Inc. He served as Director of PharmaSwiss S.A. Dr. Wicki served as Director of Cytos Biotechnology AG since June 2002. He served as a Director of HBM Healthcare Investments AG. He served as Director of Basilea Pharmaceutica AG from 2000 to April 29, 2009. He holds an M.Sc. and a Ph.D. in Chemistry and Biochemistry from the University of Bern, Switzerland in 1983. He holds doctoral thesis completed at the Theodor Kocher Institute of the University of Bern in 1986. He has been a Director of Viela Bio, Inc. since June 2019.

CEO Compensation
  • Andreas's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Andreas's remuneration is lower than average for companies of similar size in Switzerland.
Management Team

Andreas Wicki

TITLE
Chief Executive Officer
COMPENSATION
CHF172K
AGE
61
TENURE
19.3 yrs

Erwin Troxler

TITLE
Chief Financial Officer
COMPENSATION
CHF104K
AGE
49
TENURE
8.4 yrs

Benedikt Suter

TITLE
Secretary to the Board of Directors
AGE
55

Thomas Thaler

TITLE
Investment Professional
Board of Directors

Hans Hasler

TITLE
Chairman of the Board of Directors
COMPENSATION
CHF120K
AGE
63

Heinz Riesenhuber

TITLE
Vice Chairman
COMPENSATION
CHF96K
AGE
84

Benedikt Suter

TITLE
Secretary to the Board of Directors
AGE
55

Rudolf Lanz

TITLE
Member of Board of Directors
COMPENSATION
CHF70K
AGE
69
TENURE
17.3 yrs

Urs Meyer

TITLE
Member of Advisory Board

Hanns Möhler

TITLE
Member of Advisory Board

Hans Wigzell

TITLE
Member of Advisory Board
AGE
81

Gregor Zünd

TITLE
Member of Advisory Board
AGE
59

Bob Ingram

TITLE
Member of Board of Directors
COMPENSATION
CHF50K
AGE
77
TENURE
14.3 yrs

Paul Vanhoutte

TITLE
Member of Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CHF) Value (CHF)
X
Management checks
We assess HBM Healthcare Investments's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. HBM Healthcare Investments has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

HBM Healthcare Investments AG specializes in fund of funds and direct investments in middle market and mature companies. The fund prefers to invest in start up, early stage, mid stage, mid venture, late venture, and late stage private companies, unlisted emerging companies, small cap public companies, buyouts, growth capital, and private investment in public equities (PIPES). Within fund of funds, it invests in venture capital funds. It also seeks to finance spin-offs of product lines or departments from larger corporations and the expansion or restructuring of established companies, seed stages, venture capital, expansion capital stages, spin-offs, and buyouts. The fund prefers to invest in the private and public companies in the healthcare sector with a focus on human medicine, drugs, pharma , biopharma, biotechnology, diagnostics, medical technology, and related industries. It seeks to make initial investments in companies whose primary products are in clinical development or the immediately preceding stage. The fund typically invests globally with a focus on Asia Pacific, Asia, North America, and Europe. In case of public companies, it focuses on those which originate from its private portfolio. The fund increases its investment in portfolio companies by participating in a follow-on financing or after the portfolio company’s IPO. It may acquire majority participations in portfolio companies, usually takes a seat on the portfolio company’s Board of Directors, and largely makes equity investments but may also invest through other instruments including convertible bonds, debt securities, structured products, and derivatives. The fund exits its portfolio companies through trade sale or IPO.

Details
Name: HBM Healthcare Investments AG
HBMN
Exchange: SWX
Founded: 2001
CHF1,333,900,992
6,947,401
Website: http://www.hbmhealthcare.com
Address: HBM Healthcare Investments AG
Bundesplatz 1,
PO-Box 1145,
Zug,
Zug, 6301,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SWX HBMN Registered Shares SIX Swiss Exchange CH CHF 15. Feb 2008
OTCPK HBMB.F Registered Shares Pink Sheets LLC US USD 15. Feb 2008
DB 5H5A Registered Shares Deutsche Boerse AG DE EUR 15. Feb 2008
LSE 0QOC Registered Shares London Stock Exchange GB CHF 15. Feb 2008
Number of employees
Current staff
Staff numbers
0
HBM Healthcare Investments employees.
Industry
Asset Management and Custody Banks
Diversified Financials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 22:29
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/02
Last earnings filing: 2020/01/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.